20 . October , 2018 - Saturday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Lidex Topical Solution

Big Image
Generic Name: fluocinonide
Dosage Form: Topical solution

Description

Lidex solution 0.05% is intended for topical administration.  The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna - 1,4 - diene - 3,20 - dione,21 - (acetyloxy) - 6,9 - difluoro - 11 - hydroxy - 16,17 - [(1 - methylethylidene)bis(oxy)] - ,(6α,11β,16α) - . It has the following chemical structure:

Lidex topical solution contains fluocinonide 0.5 mg/mL in a solution of alcohol (35%), citric acid, diisopropyl adipate, and propylene glycol. In this formulation, the active ingredient is totally in solution.

Clinical Pharmacology

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.  There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. A significantly greater amount of fluocinonide is absorbed from the solution than from the cream or gel formulations. 

Topical corticosteroids can be absorbed from normal intact skin.  Inflammation and/or other disease processes in the skin increase percutaneous absorption.  Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.  Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.  (See DOSAGE AND ADMINISTRATION.) 

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees.  Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.  Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Indications and Usage

LIDEX® (fluocinonide) topical solution 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. 

Contraindications

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. 

Precautions

General

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.  Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, the addition of occlusive dressings, and dosage form. 

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.  If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. 

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.  Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See PRECAUTIONS—Pediatric Use.)

This preparation is not for ophthalmic use. Severe irritation is possible if fluocinonide solution contacts the eye.  If that should occur, immediate flushing of the eye with a large volume of water is recommended.

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues.  When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted.  If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. 

Information for the Patient

Patients using topical corticosteroids should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. If there is contact with the eyes and severe irritation occurs, immediately flush with a large volume of water.
  2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
  3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
  4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
  5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. 

Laboratory Tests

The following tests may be helpful in evaluating the HPA axis suppression:
        Urinary free cortisol test
        ACTH stimulation test

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy Category C

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.  The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.  There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.  Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant.  Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids.  Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.  Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen.  Chronic corticosteroid therapy may interfere with the growth and development of children.

Adverse Reactions

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings.  These reactions are listed in an approximate decreasing order of occurrence:

  
Burning
  
Itching
  
Irritation
  
Dryness
  
Folliculitis
  
Hypertrichosis
  
Acneiform eruptions
  
Hypopigmentation
  
Perioral dermatitis
  
Allergic contact dermatitis
  
Maceration of the skin
  
Secondary infection
  
Skin atrophy
  
Striae
  
Miliaria

Overdosage

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS.)

Dosage and Administration

LIDEX® (fluocinonide) topical solution 0.05% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

How Supplied

LIDEX® (fluocinonide) topical solution 0.05%
Plastic squeeze bottles
  20 cc - NDC 99207-517-44
  60 cc - NDC 99207-517-46

Store at room temperature.  Avoid excessive heat, above 40°C (104°F).

CAUTION:  Federal law prohibits dispensing without prescription.

Mfd. for:  MEDICIS®
The Dermatology Company®
Phoenix, AZ 85018

1997 MEDICIS® Dermatologics, Inc.

03517-14-01


Lidex (fluocinonide)
PRODUCT INFO
Product Code 99207-517 Dosage Form SOLUTION
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
fluocinonide (fluocinonide) Active 0.5 MILLIGRAM  In 1 MILLILITER
alcohol Inactive  
citric acid Inactive  
diisopropyl adipate Inactive  
propylene glycol Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 99207-517-44 20 MILLILITER In 1 BOTTLE, PLASTIC None
2 99207-517-46 60 MILLILITER In 1 BOTTLE, PLASTIC None

Revised: 06/2006

Recent Drug Updates at DrugIndexOnline:





Atropair Ophthalmic Atropair Ophthalmic
Some commonly used brand names are: In the U.S.— AK-Homatropine 2 Atropair 1 Atropine Care 1 Atropine Sulfate S.O.P. 1 Atropisol 1 Atrosulf 1 I-Homatrine 2 Isopto Atropine 1 Isopto Homatropine 2 Isopto Hyoscine 3 I-Tropine 1 Ocu-Tropine 1 Spectro-Homatropine 2 In Canada— Atropisol more...

Children's Children's
Some commonly used brand names are: In the U.S.— Aceta Elixir 1 Aceta Tablets 1 Acetaminophen Uniserts 1 Actamin 1 Actamin Extra 1 Actamin Super 2 Aminofen 1 Aminofen Max 1 Apacet Capsules 1 Apacet Elixir 1 Apacet Extra Strength Caplets 1 Apacet Extra Strength Tablets 1 Apacet, Infants' 1 more...

Desferal Desferal
Generic Name: deferoxamine (de fer OX a meen) Brand Names: Desferal What is Desferal (deferoxamine)? Deferoxamine binds to iron and removes it from the blood stream. Deferoxamine is used to treat iron overload caused by blood transfusions in adults and children at least 3 years old. Def more...

Econopred Econopred
Generic Name: prednisolone acetate Dosage Form: 1/8% ophthalmic suspension and 1% plus ophthalmic suspension DESCRIPTION Econopred® and Econopred® Plus (Prednisolone Acetate) are adrenocortical steroid products prepared as sterile ophthalmic suspensions. The active ingredient is represen more...

Ilozyme Ilozyme
Some commonly used brand names are: In the U.S.— Cotazym Cotazym-S Creon 5 Creon 10 Creon 20 Enzymase-16 Ilozyme Ku-Zyme HP Lipram 4500 Lipram-CR10 Lipram-PN10 Lipram-UL12 Lipram-PN16 Lipram-UL18 Lipram-CR20 Lipram-UL20 Lipram-PN20 Pancoate Pancrease Pancrease MT 4 Pancrease MT 10 Pancrea more...

Ionosol and Dextrose Ionosol and Dextrose
Generic Name: sodium chloride, potassium chloride, sodium lactate, magnesium chloride, potassium phosphate, sodium phosphate and Dextrose Dosage Form: Injection A MAINTENANCE ELECTROLYTE SOLUTION Flexible Plastic Container Rx only Ionosol and Dextrose Description Ionosol B and 5% Dextrose Injec more...

Omeprazole Delayed-Release Capsules Omeprazole Delayed-Release Capsules
Generic Name: Omeprazole Delayed-Release Capsules (oh-MEP-ra-zole) Brand Name: PrilosecOmeprazole Delayed-Release Capsules is used for:Treating heartburn or irritation of the esophagus caused by gastroesophageal reflux disease (GERD). It may also be used for short-term treatment of ulcers of the more...

Otocort Sterile Solution Otocort Sterile Solution
Generic Name: hydrocortisone, neomycin, and polymyxin B otic (hye droe CORE tih sone, nee oh MY sin, paw lee MIX in B) Brand Names: AK-Spore HC Otic Suspension, Cortatrigen, Cortatrigen Modified, Cortisporin Otic, Cortomycin, Drotic, Masporin Otic, Otimar, Otocort Sterile Solution, Otocor more...